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Abstract
Imidazolium salts have shown potential as anticancer materials. By modifying
imidazolium salts, the functionality, efficacy, and practical uses of these compounds are altered.
Several imidazolium salts were synthesized and characterized, and four compounds were
evaluated to determine their biological activity.
Chapter I investigates the synthesis and characterization of imidazolium salts with various
modifications on all five sites of the imidazole ring. Imidazolium salts were also converted to
thiones at the C2 position of the imidazole ring, thereby forming a neutral system. The recovered
products were characterized by 1H,

13

C, and

31

P NMR spectroscopy, and a select few were

evaluated by X-ray crystallography.
Chapter II assesses the biological activity of four select imidazolium salts. For these four
compounds, the GI50 values were determined via cell proliferation assays for a variety of drug
exposure times to identify effective treatment protocols. Additionally, the mechanism of action
was determined to be mitochondrially-driven by immunoblot of isolated mitochondria from cancer
cells treated with drugs of interest. Confocal microscopy was used to identify mitochondrial
polarization after treatment with mitochondrial-targeting drugs and subcellular mitochondrial
localization was observed by comparing pixel overlap of a fluorescent drug with a mitochondrial
stain. Colony forming assay was done to evaluate long-term effects on cells treated with these
compounds.
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CHAPTER I: SYNTHESIS AND CHARACTERIZATION OF IMIDAZOLIUM SALTS,
AND THIONES
Introduction
Imidazole derivatives are naturally-occurring (there is one found in the side chain of the
amino acid histidine) molecules capable of hydrogen bonding and serving as ligands to different
metal complexes, including heme centers.1 Through the alkylation of both nitrogen atoms in the
heterocycle, imidazolium salts are generated wherein the cationic imidazolium ring is resonance
stabilized and aromatic (Scheme 1.1). Imidazolium salts are easily modified, and physical
properties, such as lipophilicity or hydrophilicity, can be controlled through the alkyl groups
substituted onto the N positions of the imidazole ring. Building upon previous research from the
Youngs lab, imidazolium salts show promise as intravesical chemotherapeutics in the treatment of
a variety of cancers.2–4

Scheme 1.1: Resonance structures of a bis-alkylated imidazolium salt, showing delocalization of
charge in the imidazolium ring.
In 2020, it is estimated that there will be over 1.8 million new cancer diagnoses in the US
and more than 606,000 cancer deaths.5 There are significant side effects for many widely-used
treatments that adversely affect the patient’s quality of life after treatment; for example, cisplatin
is a treatment particularly effective against testicular cancer, but commonly leads to nephrotoxicity
and other declines in organ function.6,7 Long-term systemic damage is typical for many cancer
treatments, and is to be avoided. Surgery is the standard for intervention, but may lead to
recurrence and metastases from the wound-healing process.8,9
Imidazolium salts have been shown previously to be cytotoxic against a variety of cell lines
for non-small cell lung cancer.3,10–12 Of these drugs, those that have shown the highest activity
3

against cancer cell lines are bis-methylnaphthyl systems in the 1 and 3 positions of the imidazolium
ring (Figure 1.1).2 Additionally, the exfoliative properties of imidazolium salts have been
elucidated against uroepithelial luminal cells.13 Imidazolium cations can be functionalized in the
C2 position as well, which can be beneficial for its use both in vivo and in vitro, possibly enabling
the drug to target organelles of interest within the cell or give the molecule fluorescent properties.
Given that the mitochondria in cancer cells are more active and more polarized than normal cells,
targeting the mitochondria is a possible mechanism for cell selectivity; moreover, mitochondrial
and metabolic differences between cancerous and normal tissues may enable selective cytotoxicity
of the drug.14–16

Figure 1.1: Bis(methylnaphthyl) imidazolium cation with substituents R2 in the C2 position, R4 in
the C4 position, and R5 in the C5 position. These R groups can be modified to change properties
including lipophilicity and biological activity.

To generate an imidazole derivative with different substituents in the C2 position, a DebusRadziszewski reaction can be used as described in the literature.17 In this particular reaction, a
diamine is reacted with an aldehyde, carboxylic acid, or ester to synthesize an imidazole. The
general reaction is shown in Scheme 1.2. The Debus-Radziszewski reaction is practical for the
polymerization of certain molecules and in synthetic work with a variety of biomaterials. 18,19 In a
different method to functionalize the C2 position, a 2-methyl imidazolium salt is reacted with
strong base whereby the methyl group is deprotonated, making it a good Michael donor in
subsequent reactions with α,β-unsaturated carbonyls or other Michael acceptors.20 Although not
an enolate, resonance stabilization of this compound enables its use in Stork enamine syntheses.
4

Scheme 1.2: General Debus-Radziszewski reaction to synthesize an imidazole using catalytic
acid.21

When reacting a 2-H imidazolium salt with a base, a stable carbene is generated on the C2
atom, as first isolated by Arduengo.22 This generated N-heterocyclic carbene (NHC) is a good
ligand that binds to metal centers in a strong σ-donor fashion.23,24 The formation of silver carbene
complexes (SCCs) is done by reacting NHCs with Ag(I) species, and SCCs have shown
tremendous potential as antimicrobial agents.25,26 NHCs also have practical uses as ligands for a
variety of different catalysts for different couplings and reactions. 27,28
Results and Discussion
Synthesis and Characterization of Imidazolium Salts
Compounds 1-4 were synthesized according to the reaction shown in Scheme 1.3. These
products were synthesized in a similar manner to literature reactions and previous work of the
Youngs group.2,3,13 The imidazole is first treated with base and subsequently an alkyl halide to
form the mono-substituted intermediate. The mono-product is then alkylated further in refluxing
acetonitrile to form the imidazolium salt.
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Scheme 1.3: Reaction for the synthesis of products 1-4. All reactions were run in acetonitrile
heated to a reflux.

To determine if the imidazolium salt was generated, products were examined via 1H NMR,
and Figure 1.2 shows the 1H spectra for both the mono-product and imidazolium salt 3. The
characteristic shift at 9.59 ppm in the 1H spectrum for 3 is indicative of the C2 proton, the hydrogen
atom bonded to the C2 carbon of the heterocycle. This shift is downfield due to the delocalized
positive charge deshielding the proton, and the presence of this shift indicates the generation of
the imidazolium salt. Additionally, the downfield transition of the methylene shift from 5.40 ppm
in the mono-product to 5.71 ppm in 3 validates the synthesis of the imidazolium salt. This trend
follows for all products 1-4.
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Figure 1.2: 1H NMR spectrum of 3 (bottom) and its mono product (top) displaying the downfield
transition of the methylene shift and the presence of the characteristic C2 proton in the imidazolium
salt. Each spectrum was standardized to DMSO (2.50 ppm).
Different substituents in the C4 and C5 positions of the imidazole have a role in the
lipophilicity and biological activity of the imidazolium salt against cancer cell lines. Compound 5
has a benzimidazole core, which results in decreased water solubility in comparison to 3.
Compound 5 was synthesized in accordance to the reaction shown in Scheme 1.4, where KBr was
removed from the solution after the first alkylation. The characteristic C2 proton resonance
presents at 10.20 ppm.

Scheme 1.4: Reaction conditions for the synthesis of 5 from benzimidazole.
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Other benzimidazole derivatives were used to synthesize imidazolium salts and were
generated via a Debus-Radziszewski synthesis. Scheme 1.5 details the synthesis of 6 and 7,
benzimidazole derivatives with different substituents in the C2 position. No acid was used in the
synthesis of 6, but the synthesis of 7 was run in refluxing 4 M HCl.

Scheme 1.5: Synthesis of 6 and 7 via a Debus-Radziszewski imidazole synthesis.

Compounds 6 and 7 were subsequentially alkylated to yield the products 8 and 9,
respectively (Scheme 1.6). In the synthesis of 8, sodium carbonate is used as a base instead of
hydroxide. Given the aryl halide in 6, care was taken to assure that the base was not nucleophilic
to avoid nucleophilic aromatic substitution.
Compound 8 is of particular interest for further functionalization due to the aryl bromide
in the C2 position. The aryl bromide can be substituted with an amine via Buchwald-Hartwig
couplings or with an alkyne using a Sonogashira coupling, thus allowing for functionalization para
to the imidazolium cation. One drawback to these couplings is the imidazolium cation is electron
withdrawing and deactivates the C2 phenyl ring, so special palladium catalysts are required for
these couplings to proceed in acceptable yields.
8

Scheme 1.6: Synthesis of 8 and 9 from 6 and 7, respectively. Reactions were refluxed in
acetonitrile.

Product 9 was functionalized to contain a triphenylphosphonium moiety, enabling its
targeting of the mitochondria in treated cells. Triphenylphosphine is nucleophilic and can be
substituted onto 9 via an SN2 mechanism, but the alcohol must first be converted to a better leaving
group. To do this, the alcohol was reacted with thionyl bromide, forming the alkyl bromide, then
reacted with triphenylphosphine to synthesize 10 (Scheme 1.7).
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Scheme 1.7: Synthesis of 10 from 9 using thionyl bromide and triphenylphosphine. The resulting
product is the dibromide salt.

Product 10 was evaluated by 1H, 13C, and 31P NMR. Evidenced by the downfield movement
of the propyl shifts in 10, the reaction formed a triphenylphosphonium cation. The formed cation
decreases electron density in the propyl chain, thereby deshielding the corresponding H atoms and
pushing those shifts downfield (Figure 1.3A and 1.3B). Using

31

P NMR spectroscopy (Figure

1.4C), a single shift was observed at 23.30 ppm. Typically, to reference a 31P NMR spectrum run
in DMSO, phosphoric acid is added to the sample; however, this NMR spectrum was obtained to
verify that there was no unreacted triphenylphosphine or phosphine oxide compounds present in
the sample. The observation of a single shift confirms that there are no phosphorus-containing
impurities in the sample, and given that it is distinct from triphenylphosphine, it was concluded
that 10 was isolated. Although not applicable to most biological systems, it is necessary to avoid
using strong base with 10 as the corresponding ylide would be generated and could react as a
Wittig reagent.
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Figure 1.3: (A) 1H NMR spectrum of 9, with DMSO solvent at 2.50 ppm. (B) 1H NMR spectrum of
10, where the propyl shifts are observed farther downfield than that for 9. (C) 31P NMR spectrum
of 10 revealing a single shift at 23.3 ppm. This was not referenced to phosphoric acid and was
done to ensure that there was no unreacted triphenylphosphine or phosphine oxide present in the
sample.
Further characterization was done for 10 as single crystals were examined via x-ray
crystallography. The thermal ellipsoid plot of 10 is shown in Figure 1.4 with ellipsoids drawn at
50% probability. The crystal structure was monoclinic with space group P21/n, and the structure
parameters are included in Table 1.1.
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Figure 1.4: Thermal ellipsoid plot of 10 with ellipsoids drawn at 50% probability. H atoms were
omitted for clarity.

With the intention of using these imidazolium salts for the treatment of cancer in vivo,
water solubility plays a vital role in the practicality of the compound. Imidazolium salts 1-5 and
8-10 all have different substituents on the imidazolium ring. Compound 10 is hygroscopic, and the
addition of the triphenylphosphonium moiety marks an increase in its water solubility.
Synthesis and Characterization of C2 Functionalized Thiones
To generate 2-thione imidazole compounds, 2-H imidazolium salts were reacted with S8
and potassium carbonate. After refluxing this in methanol, the reaction mixture is decanted,
leaving behind a yellow solid believed to be unreacted S8. The reaction mixture is filtered to collect
the crude product as a solid. The solid is washed in boiling water to remove unreacted K2CO3 and
filtered again. This solid was washed with boiling hexanes to remove any sulfur that remains.
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Scheme 1.8 details the synthesis of thiones 11 and 12 starting from imidazolium salts 3 and 4,
respectively. 12 was characterized via 1H and 13C NMR spectroscopy, and the 1H spectrum was
compared against 4, the starting imidazolium salt (Figure 1.5). The upfield shift of the methylene
peak from 5.71 to 5.56 ppm between 3 and 11 and from 5.63 to 5.39 ppm between 4 and 12 is
indicative of the formation of the thione. By forming the neutral system, the electronic
environment of the imidazole ring was altered, pushing the methylene shift upfield. Also shown
in Figure 1.7, the C2 proton resonance is no longer present in the 1H NMR of 12, thus leading to
the conclusion that the resulting product was functionalized in this position.

Scheme 1.8: Synthesis of 11 and 12 starting from imidazolium salts 3 and 4, respectively. Crude
product was washed in boiling water to remove potassium salts and then washed in boiling
hexanes to remove excess sulfur.
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Figure 1.5: 1H NMR of 4 (top) and 12 (bottom), illustrating the changes in electron density of
the imidazole and the functionalization of the C2 position, as the resonance observed for the C2
proton in 4 is not observed for 12.
To confirm the structure of 12, suitable single crystals of 12 were analyzed by X-ray
crystallography, and the thermal ellipsoid plot of 12 is shown in Figure 1.6 and structure
parameters included in Table 1.1. Compound 12 was orthorhombic with a space group of Pnma.

Figure 1.6: Thermal ellipsoid plot of 12 with hydrogen atoms removed for clarity. Thermal
ellipsoids are drawn to 50% probability.
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Compound
10
12
Empirical formula
C52H51Br2N2P
C100H80N8S4
Formula weight
926.74
1521.96
Crystal system
Monoclinic
Orthorhombic
Space group
P21/n
Pnma
a (Å)
10.8583(2)
7.8922(8)
b (Å)
34.0758(6)
31.566(3)
c (Å)
12.9337(13)
7.7041(7)
α (°)
90
90
β (°)
112.0353(10)
90
γ (°)
90
90
3
Volume (Å )
4435.97(13)
1919.3(3)
Z
4
1
Reflections collected
50384
18390
Independent reflections
9015
1984
Rint
0.1152
0.1275
Final R1 values (I>2σ(I))
0.0502
0.0554
wR(F2) values (I>2σ(I))
0.0869
0.1287
Final R1 values (all data)
0.1017
0.0953
wR(F2) values (all data)
0.1055
0.1576
Table 1.1: Structure parameters for 10 and 12 elucidated from X-ray crystallography.

Another thione, 13, was synthesized using a different method than the synthesis of 11 and
12 (Scheme 1.9). In this reaction, hydroxide acts as both a nucleophile and a base, as methanol is
formed in this reaction. The intermediate imidazolium anion is resonance stabilized, making it a
good leaving group when hydroxide attacks the methyl group. The nitrogen atom acts as the
nucleophile in the second alkylation much more readily than the sulfur atom, despite both sharing
the negative charge.
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Figure 1.9: Synthesis of 13 from 2-(methylthio)benzimidazole. The intermediate anion is
resonance stabilized, and the nitrogen atom acts as a nucleophile much more readily than the
sulfur atom in the second alkylation.
These imidazolium thiones can act as a ligands, and Ag-thione systems can be
generated.29,30 Several Ag-thione systems have been synthesized, including silver(I) acetate and
silver(I) triflate systems, and are awaiting analysis via X-ray crystallography.
Conclusions
Several imidazolium salts were synthesized with different functional groups in the C2, C4,
and C5 positions of the imidazole ring, which changed the lipophilicity of the imidazolium salt. In
order to increase the lipophilicity of these imidazolium salts, benzimidazole cores were added to
these salts or phenyl groups in the C2, C4, or C5 positions should result in an increase in biological
activity against cancer cell lines. Compounds 3 and 10 are of special interest to the group and were
evaluated in detail in Chapter II.
To characterize imidazolium salts without any functionalization in the C2 position, there is
a singlet resonance downfield in the 1H NMR spectra (with greater than 9 ppm) and this carbon
presents as the furthest downfield shift in

13

C NMR spectra. Another feature of 1H spectra to

confirm the formation of the imidazolium salt is the methylene shift will move downfield in
16

comparison to its mono product. Complete structure elucidation for 10 and 12 was done by solving
the crystal structure of such compounds.
Several C2 thiones were synthesized and characterized as well. These thiones are a neutral
system and are conjectured to have decreased activity against cancer cell lines but can form Ag(I)thione complexes. These thione systems were made from precursor imidazolium salts, and the
thione was confirmed with the removal of the C2 proton shift in the thione product.
Experimental Section
General Considerations
All reactions were carried out under aerobic conditions unless otherwise specified. All
solvents and reagents were purchased from commercial sources (VWR, Fisher Scientific, Sigma,
Beantown Chemical, Alfa Aesar) with no further purification performed. 1H, 13C, and 31P nuclear
magnetic resonance (NMR) spectra were collected on a Varian 300 or 400 MHz instrument and
were referenced to DMSO-d6 (Cambridge Isotope Laboratories, (δ = 2.50 ppm, 39.51 ppm). 31P
NMR spectra were not referenced with phosphoric acid, and this was done to assure that there
were no contaminants in the sample.
Crystal structures were obtained by Michael L. Stromyer. Single crystals suitable for
diffraction were coated in Paratone oil and mounted on a CryoLoop, then placed onto the
goniometer under a stream of nitrogen. Data sets were collected on a Bruker APEX diffractometer
with Mo Kα radiation (λ = 0.71073 Å). Data integration and reduction were performed using the
APEX II software suite.
Synthesis of 4,5-dichloro-1,3-dimethyl-1H-imidazolium iodide (1): To 35 mL of
acetonitrile, 4,5-dichloroimidazole (1.86 g, 13.6 mmol) was added with KOH (2.24 g, 40.0 mmol)
and allowed to reflux for 45 min. Methyl iodide (1.000 mL, 2.28 g, 16.1 mmol) was added to the
17

reaction mixture and the solution was stirred at room temperature for 70 h. The reaction suspension
was filtered, removing a solid that was presumed to be KI. The filtrate volatiles were removed
under reduced pressure, leaving a yellow oil. To the oil, a 50 mL portion of acetonitrile and methyl
iodide (4.000 mL, 9.12 g, 64.3 mmol) was added and the solution was refluxed for 24 h. The
reaction was cooled and filtered, and a brown solid was recovered. To remove methyl iodide, the
solid was placed on top of a warm oven, evaporating excess CH3I. The solid was washed twice
with 25 mL of acetone to give 1 as a white powder (3.17 g, 80%). 1H NMR (300 MHz, DMSOd6): δ 9.37 (s, 1 H, NCHN), 3.81 (s, 6 H, CH3).
Synthesis of 1,3-bis(naphthalen-2-ylmethyl)-4,5-diphenyl-1H-imidazolium bromide
(2): To 25 mL of acetonitrile, 4,5-diphenylimidazole (2.033 g, 9.23 mmol) and KOH (0.520 g,
9.27 mmol) were added and refluxed for 15 min. To the reaction solution, 2(bromomethyl)naphthalene (2.072 g, 9.37 mmol) was added and refluxed for 3 h. The reaction
suspension was filtered hot to remove the solid presumed to be KBr, and the green filtrate was
recovered. Additional 2-(bromomethyl)naphthalene (2.224 g, 10.1 mmol) was added to the filtrate
solution and the reaction was refluxed for 20 h. The reaction suspension was cooled to room
temperature and 2 was recovered as a white solid via vacuum filtration and air-dried overnight
(4.41 g, 82%). 1H NMR (400 MHz, DMSO-d6): δ 9.79 (s, 1 H, NCHN), 7.92-7.89 (m, 4 H, Ar),
7.82-7.80 (m, 2 H, Ar), 7.59 (s, 2 H, Ar), 7.54-7.52 (m, 4 H, Ar), 7.37-7.30 (m, 12 H, Ar), 5.60 (s,
4 H, CH2).
Synthesis of 4,5-dichloro-1,3-bis(naphthalen-2-ylmethyl)-1H-imidazolium bromide
(3): To a 25 mL portion of acetonitrile, 4,5-dichloroimidazole (1.02 g, 7.45 mmol) and KOH (0.51
g, 9.11 mmol) were added and the suspension was refluxed for 30 min. To the reaction solution,
2-(bromomethyl)naphthalene (1.64 g, 7.42 mmol) was added and the solution was refluxed for 20
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h. The reaction suspension was filtered hot, which removed the solid presumed to be KBr. The
filtrate volatiles were removed under reduced pressure. To the recovered solid, a 25 mL portion of
acetonitrile and 2-(bromomethyl)naphthalene (1.60 g, 7.24 mmol) were added and the suspension
was refluxed for 22 h. The reaction suspension was filtered hot, recovering a white solid . The
solid was stirred in 30 mL of dry diethyl ether, recovered by filtration, and dried over aspirator
suction. Product 3 was recovered as a white solid (2.11 g, 59%). 1H NMR (400 MHz, DMSO-d6):
δ 9.80 (s, 1 H, NCHN), 8.03-7.94 (m, 8 H, Ar), 7.61-7.57 (m, 6 H, Ar), 5.71 (s, 4 H, CH2). 13C
NMR (400 MHz, DMSO-d6): δ 137.4, 133.2, 133.1, 130.5, 129.2, 128.3, 128.1, 127.3, 127.2,
126.0, 119.8, 52.3.
Synthesis of 1,3-bis(naphthalen-2-ylmethyl)-1H-imidazolium bromide (4): To 25 mL
of acetonitrile, imidazole (1.45 g, 21.3 mmol) and KOH (1.29 g, 23.0 mmol) were added and
refluxed for 20 min. To the reaction solution, 2-(bromomethyl)naphthalene (4.78 g, 21.6 mmol)
was added and the solution was refluxed for 20 h. The reaction suspension was filtered hot, thereby
removing the solid presumed to be KBr. The filtrate volatiles were removed under reduced
pressure, yielding an off-white solid as the mono product (3.79 g, 85%). The mono product (1.76
g, 8.45 mmol) and 2-(bromomethyl)naphthalene (2.07 g, 9.35 mmol) were added to 25 mL of
acetonitrile and this solution was refluxed for 22 h. The reaction suspension was filtered, removing
a white solid. This solid was washed with 40 mL of dry diethyl ether, dried over aspirator suction,
and 4 was recovered as a white solid (1.80 g, 50%). 1H NMR (400 MHz, DMSO-d6): δ 9.54 (s, 1
H, NCHN), 8.00-7.98 (d, 2 H, Ar), 7.97 (s, 2 H, Ar), 7.96-7.93 (m, 2 H, Ar), 7.92-7.90 (m, 4 H,
Ar), 7.58-7.56 (m, 4 H, Ar), 7.54-7.53 (d, 2 H, Ar), 5.63 (s, 4 H, CH2).
Synthesis of 1,3-bis(naphthalen-2-ylmethyl)-1H-benzimidazolium bromide (5): To 65
mL of acetonitrile, benzimidazole (3.41 g, 28.8 mmol) and KOH (1.81 g, 32.3 mmol) were added
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and the solution was refluxed for 30 min. 2-(bromomethyl)naphthalene (6.53 g, 29.5 mmol) was
added and the suspension was refluxed for 24 h. The reaction suspension was filtered hot,
removing a solid presumed to be KBr. To the filtrate, 2-(bromomethyl)naphthalene (7.40 g, 33.5
mmol) was added and the reaction was refluxed for 18 h. The reaction suspension was filtered hot,
removing a white solid. The crude product was stirred in 50 mL dry diethyl ether and the solid was
dried in the oven, recovering 5 as a white solid (9.56 g, 69%). 1H NMR (400 MHz, DMSO-d6): δ
10.20 (s, 1 H, NCHN), 8.11 (s, 2 H, Ar), 8.00-7.98 (q, 2 H, Ar), 7.95-7.93 (d, 2 H, Ar), 7.91-7.87
(q, 2 H, Ar), 7.62 (d, 2 H, Ar), 7.60-7.59 (d, 2 H, Ar), 7.58-7.55 (q, 2 H, Ar), 7.53-7.50 (m, 4 H,
Ar), 5.96 (s, 4 H, CH2).
Synthesis of 2-(4-bromophenyl)-1H-benzimidazole (6): To a 35 mL portion of DMF, 4bromobenzaldehyde (4.43 g, 23.9 mmol) and o-phenylenediamine (2.66 g, 24.6 mmol) were added
and the solution was refluxed for 18 h. The hot reaction solution was decanted into 100 mL of ice
water and a brown precipitate formed upon mixing. The ice was allowed to melt, and contents of
the flask were filtered. The crude product was washed with 40 mL of diethyl ether, dried with
aspirator suction, and 6 was recovered as a light tan solid (3.07 g, 46%). 1H NMR (400 MHz,
DMSO-d6): δ 12.92 (s, 1 H, NH), 8.08-8.05 (d, 2 H, Ar), 7.72-7.70 (d, 2 H, Ar), 7.62-7.49 (m, 2
H, Ar), 7.17-7.16 (d, 2 H, Ar).
Synthesis of 3-(1H-benzimidazol-2-yl)propan-1-ol (7): To 5 mL of 4 M HCl, ophenylenediamine (1.00 g, 9.25 mmol) and γ-butyrolactone (0.775 mL, 0.868 g, 10.1 mmol) were
added and the solution was refluxed for 2 h. A 20 mL portion of saturated Na2CO3 solution was
added to the reaction solution and the solution turned orange as the acid was neutralized. The
reaction flask was allowed to sit for 15 minutes, and a pale red precipitate formed. The solid was
filtered, air-dried overnight, and 8 was recovered (0.30 g, 18%). 1H NMR (400 MHz, DMSO-d6):
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δ 7.46-7.44 (m, 2 H, Ar), 7.11-7.09 (m, 2 H, Ar), 3.51-3.48 (t, 2 H, CH2OH), 2.87-2.83 (t, 2 H,
CH2), 1.96-1.89 (p, 2 H, CH2).
Synthesis

of

2-(4-bromophenyl)-1,3-bis(naphthalen-2-ylmethyl)-1H-

benzimidazolium bromide (8): To a 25 mL portion of acetonitrile, compound 7 (1.33 g, 4.86
mmol), sodium bicarbonate (0.81 g, 9.64 mmol), and 2-(bromomethyl)naphthalene (1.18 g, 5.36
mmol) were added and the suspension was refluxed for 20 h. The reaction suspension was filtered
hot to remove a solid that was presumed to be NaBr and the filtrate volatiles were removed under
reduced pressure, yielding a brown oil. To this oil, a 20 mL portion of acetonitrile was added with
additional 2-(bromomethyl)naphthalene (1.17 g, 5.30 mmol), and the reaction flask was refluxed
for 20 h. The reaction was cooled, and reaction volatiles were removed under reduced pressure,
yielding a brown oil. This oil was dissolved into a 20 mL portion of dry methylene chloride, and
a 50 mL portion of dry diethyl ether was added to the solution, forming a tan precipitate. The solid
was collected via vacuum filtration and dried under vacuum to give 7 as a tan solid (1.97 g, 64%).
1

H NMR (400 MHz, DMSO-d6): δ 8.09-8.05 (m, 2 H, Ar), 7.92-7.89 (m, 8 H, Ar), 7.84-7.81 (m,

2 H, Ar), 7.76 (s, 2 H, Ar), 7.70-7.67 (m, 2 H, Ar), 7.55-7.50 (m, 4 H, Ar), 7.38-7.35 (m, 2 H, Ar),
5.82 (s, 4 H, CH2).
Synthesis

of

2-(3-hydroxypropyl)-1,3-bis(naphthalen-2-ylmethyl)-1H-

benzimidazolium bromide (9): Product 8 (1.52 g, 8.65 mmol) and KOH (0.98 g, 17.5 mmol)
were added to a 40 mL portion of acetonitrile and this solution was refluxed for 30 min. To the
solution, 2-(bromomethyl)naphthalene (2.00 g, 9.05 mmol) was added, and the reaction solution
was refluxed for 16 h. The reaction suspension was filtered hot, removing a solid that was
presumed to be KBr, and the filtrate volatiles were removed under reduced pressure, giving a solid
intermediate. To the solid, a 10 mL portion of acetonitrile and 2-(bromomethyl)naphthalene (1.93
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g, 8.71 mmol) were added and the solution was refluxed for 24 h. The reaction was filtered hot,
and a white solid was collected. This solid was washed with a 10 mL portion of diethyl ether and
allowed to air dry, yielding 9 as a white solid (3.12 g, 67%). 1H NMR (300 MHz, DMSO-d6): δ
8.00 (s, 2 H, Ar), 7.98-7.86 (m, 8 H, Ar), 7.57-7.51 (m, 6 H, Ar), 7.48-7.47 (d, 2 H, Ar), 6.09 (s, 4
H, NCH2), 4.82 (s, 1 H, OH), 3.57-3.53 (t, 2 H, CH2), 3.50-3.46 (t, 2 H, CH2), 1.79-1.71 (p, 2 H,
CH2).
Synthesis of 1,3-bis(naphthalen-2-ylmethyl)-2-(3-(triphenylphosphonio)propyl)-1Hbenzimidazolium bromide (10): A solution of 24 mL of dry methylene chloride and 0.5 mL of
dry DMF was cooled in an ice bath, and product 9 (1.00 g, 1.87 mmol) was added and dissolved.
Thionyl bromide (1.500 mL, 4.04 g, 19.4 mmol) was added dropwise to the reaction flask and the
solution was stirred at room temperature for 24 h. The resulting solution was washed three times
with 40 mL portions of diethyl ether, leaving a thick orange oil. This oil was dissolved into 50 mL
of dry acetonitrile, and triphenylphosphine (4.02 g, 15.3 mmol) was added. The solution was
refluxed for 24 h. The reaction suspension was removed from heat, placed in an ice bath, and
filtered when cold. The filtrate was collected, and filtrate volatiles were removed under reduced
pressure. To the recovered product, a 20 mL portion of methylene chloride was added, and this
suspension was filtered. A 15 mL portion of diethyl ether was added to the filtrate, and this
suspension was filtered. The recovered solid was washed with water and stirred in 15 mL of diethyl
ether for 20 h. The suspension was filtered, the solid was dried over aspirator suction, and 10 was
recovered as a light tan solid (0.468 g, 29%). 1H NMR (400 MHz, DMSO‑d6): δ 7.94-7.92 (m, 2
H, Ar), 7.90-7.86 (m, 6 H, Ar), 7.82-7.80 (m, 2 H, Ar), 7.75-7.72 (m, 3 H, Ar), 7.59-7.54 (m, 18
H, Ar), 7.47 (d, 2 H, Ar), 6.15 (s, 4 H, NCH2), 4.05-3.94 (m, 4 H, CH2), 1.90-1.86 (p, 2 H, CH2).
13

C NMR (400 MHz, DMSO‑d6): δ 153.2, 134.5, 133.0, 132.8, 132.4, 132.1, 131.5, 131.2, 129.8,
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129.7, 128.3, 127.4, 126.3, 125.1, 124.4, 117.8, 117.0, 113.4, 48.6, 24.1, 20.3, 20.1. 31P NMR (300
MHz, DMSO‑d6): δ 23.3.
Crystal data for 10: C52H51Br2N2P, M = 926.74, monoclinic, a = 10.8583(2) Å, b =
34.0758(6) Å, c = 12.9337(13) Å, β = 112.0353(10)°, V = 4435.97(13) Å3, T = 100(2) K, space
group P21/n, Z = 4, 50384 reflections measured, 9015 independent reflections (Rint = 0.1152). The
final R1 values were 0.0502 (I>2σ(I)). The final wR(F2) values were 0.0869 (I>2σ(I)). The final
R1 values were 0.1017 (all data). The final wR(F2) values were 0.1055 (all data).
Synthesis of 4,5-dichloro-1,3-bis(naphthalen-2-ylmethyl)-1,3-dihydro-2H-imidazole2-thione (11): Compound 3 (2.00 g, 4.02 mmol), S8 (1.04 g, 4.06 mmol), and K2CO3 (0.67 g, 4.86
mmol) were added to a 35 mL portion of methanol and the suspension was refluxed for 16 h. The
reaction was removed from heat and decanted, thereby removing any unreacted sulfur. Volatiles
from the reaction solution were removed under reduced pressure, giving a tan solid. The solid was
washed twice with 100 mL portions of boiling water and washed twice with 25 mL portions of
boiling hexanes. Solid 11 was recovered via vacuum filtration and dried over aspirator suction
(1.54 g, 85%). 1H NMR (400 MHz, DMSO-d6): δ 7.90-7.83 (m, 6 H, Ar), 7.76 (s, 2 H, Ar), 7.517.47 (m, 6 H, Ar), 5.56 (s, 2 H, CH2).
Synthesis of 1,3-bis(naphthalen-2-ylmethyl)-1,3-dihydro-2H-imidazole-2-thione (12):
To a 30 mL portion of methanol, compound 4 (1.78 g, 4.15 mmol), K2CO3 (0.67 g, 4.82 mmol),
and S8 (1.01 g, 3.95 mmol) were added and the suspension was refluxed for 24 h. The reaction
suspension was removed from heat and decanted, leaving behind a yellow solid assumed to be
unreacted S8. Volatiles were removed under reduced pressure, leaving an off-white colored solid.
This solid was washed in with a 100 mL portion of boiling water to remove excess potassium
carbonate. The solid was washed with a 40 mL portion of boiling hexanes to remove residual sulfur
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and filtered. The recovered solid was dried over aspirator suction, giving 12 as a white powder
(1.27 g, 85%). 1H NMR (400 MHz, DMSO-d6): δ 7.87-7.80 (m, 6 H, Ar), 7.75 (s, 2 H, Ar), 7.487.45 (m, 6 H, Ar), 7.21 (s, 2 H, NCH), 5.39 (s, 4 H, CH 2).

13

C NMR (400 MHz, DMSO-d6): δ

162.6, 134.6, 132.8, 132.4, 128.2, 127.7, 127.6, 126.4, 126.1, 125.8, 118.0, 50.2.
Crystal data for 12: C100H80N8S4, M = 1521.96, orthorhombic, a = 7.8922(8) Å, b =
31.566(3) Å, c = 7.7041(7) Å, α = 90°, β = 90°, γ = 90°, V = 1919.3(3) Å3, T = 100(2) K, space
group Pnma, Z = 1, 18390 reflections measured, 1984 independent reflections (Rint = 0.1275). The
final R1 values were 0.05554 (I>2σ(I)). The final wR(F2) values were 0.1287 (I>2σ(I)). The final
R1 values were 0.0953 (all data). The final wR(F2) values were 0.1576 (all data).
Synthesis of 1,3-bis(naphthalen-2-ylmethyl)-1,3-dihydro-2H-benzimidazole-2-thione
(13): In a 30 mL portion of acetonitrile, 2-(methylthio)benzimidazole (5.00 g, 30.5 mmol) and
KOH (2.43 g, 43.3 mmol) were added and the solution was refluxed for 30 min. To the reaction
solution, 2-(bromomethyl)naphthalene (7.64 g, 34.5 mmol) was added and the solution was
refluxed for 2.5 h. The reaction suspension was filtered hot to remove a solid presumed to be KBr,
and additional 2-(bromomethyl)naphthalene (7.71 g, 34.9 mmol) was added to the filtrate. The
reaction solution was refluxed for 16 h and filtered hot, removing a white solid. This solid was
washed with a 30 mL portion of cold acetonitrile, a 100 mL portion of diethyl ether, and air-dried
overnight, yielding 13 as a white solid (8.48 g, 65%). 1H NMR (400 MHz, DMSO-d6): δ 7.90-7.83
(m, 8 H, Ar), 7.56-7.54 (dd, 2 H, Ar), 7.52-7.46 (m, 4 H, Ar), 7.41-7.38 (m, 2 H, Ar), 7.16-7.12
(m, 2 H, Ar), 5.83 (s, 4 H, CH2).
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CHAPTER II: BIOLOGICAL EVALUATION OF SELECT IMIDAZOLIUM SALTS
AGAINST BLADDER CANCER CELL LINES
Introduction
Urinary bladder cancer is expected to be diagnosed in more than 80,000 patients (over 75%
men) in the United States in 2020 and lead to nearly 18,000 deaths, with more than 70% of new
diagnoses being designated as nonmuscle invasive bladder cancer (NMIBC). 5,31 Several
intravesical treatments have been approved for the treatment of NMIBC, but bladder cancer
recurrence remains a major issue.32 Most notably, intravesical instillation of Bacillus CalmetteGuérin (BCG), an avirulent immunotherapy derived from Mycobacterium bovis, is the standard of
care for high-risk superficial tumors; however, insufficient production of BCG limits its clinical
use.33–35 Further, high recurrence rates associated with BCG immunotherapy often lead to more
radical forms of treatment, including cystectomy (removal of the bladder). 36,37 For patients with
superficial bladder cancer who received BCG treatment, complications still arise.38 Provided these
issues associated with current NMIBC treatments, there is a need for new intravesical therapies
(i.e. administered directly into the bladder lumen).
The intrinsic mitochondrial pathway for apoptosis is controlled by the Bcl-2 protein family,
which induces apoptosis through either organelle dysfunction or the caspase pathway (Figure
2.1).39–41 In the presence of mitochondrial distress, proapoptotic Bax and Bak translocate from the
cytoplasm to the mitochondria and oligomerize, forming mitochondrial transmembrane pores.42–
45

This opening of mitochondrial pores results in the depolarization of the cell and expulsion of

cytochrome c from the inner membrane of the mitochondria to the cytosol. 46,47 Once in the cytosol,
cytochrome c complexes with Apaf-1 (apoptotic protease activating factor) to activate pro-caspase
9, the initiator caspase that triggers a proteolytic cascade resulting in apoptosis, the irreversible
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autodigestion of the cell.48–52 Caspase 9, once activated, cleaves effector caspases 3 and 7, and
their activation leads to apoptosis.53–55 Caspase 3 and caspase 7 have distinct roles within the cell,
and both are pivotal in the proteolytic cascade.56

Figure 2.1: Intrinsic mitochondrial pathway of apoptosis initiated by a mitochondrial-targeting
drug. Mitochondrial drug triggers cytochrome c release from the inner membrane of the
mitochondria to the cytosol, triggering a proteolytic cascade resulting in apoptosis.

There are several drugs and small molecules that induce apoptosis through the intrinsic
mitochondrial pathway. One such compound is CCCP (carbonyl cyanide m-chlorophenyl
hydrazone, Figure 2.2), a protonophore that depolarizes the mitochondria, resulting in cytochrome
c release into the cytosol.57 Additionally, the interactions of synthetic and naturally-occurring
small molecules with mitochondrial pores and Bcl-2 have been studied.58,59 F16 (Figure 2.2), a
delocalized lipophilic cation, is a plant-derived extract from Eurycoma longifilia that inhibits the
proliferation of cells overexpressing specific oncogenes in breast cancers and solid epithelial
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tumors.60–63 One imidazolium salt, 3, has shown high activity against cancer cell lines as well
(Figure 2.3).2

Figure 2.2: Structures of CCCP (left), a protonophore known to cause mitochondrial
depolarization, and F16 (right), a naturally occurring delocalized lipophilic cation shown to
induce apoptosis in cells through a mitochondrial mechanism.

Figure 2.3: Structure of 3, an imidazolium salt with potential as an intravesical treatment for
NMIBC.

Alternatively, modifications including the addition of triphenylphosphonium (TPP) cations
to chemotherapeutics or biomolecules facilitate the accumulation of the drug in the mitochondria
and is a viable method for overcoming multidrug resistance.64–67 One TPP-containing imidazolium
salt, 10 (Figure 2.4), was investigated.4 TPP compounds are particularly efficient at targeting
mitochondria because they are lipophilic enough to permeate lipid bilayers, yet positively charged
and attracted to the negative mitochondrial membrane potential.68,69 The delocalization of the
positive charge plays a pivotal role in mitochondrial targeting as well. 70
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Figure 2.4: Structure of imidazolium salt functionalized with TPP-moiety, 10.

As an alternative to TPP substituents, a cyanine dye can be synthesized by functionalizing
the 2-position of the imidazole ring. Cyanine dyes consist of conjugated π-systems enabling π to
π* transitions for fluorescence, which can be utilized in the determination of its subcellular
localization.71,72 TCK1 is an imidazolium salt functionalized to be a cyanine dye (Figure 2.5). One
cyanine dye, JC-1 (Figure 2.6), is a common fluorescent probe for confocal microscopy since it
has two different maximum emission wavelengths that are dependent on the mitochondrial
membrane potential (MMP).73,74 Furthermore, JC-1 has a maximum emission of 590 nm as the Jaggregate at high MMP, but maximum emission of 490 nm in its monomeric state at low MMP;
thus, the hyperpolarization or depolarization of the cell’s mitochondria can be monitored. 75,76

Figure 2.5: Structure of TCK1, an imidazolium salt functionalized to be a cyanine dye. This
compound was synthesized by Michael Stromyer.77
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Figure 2.6: Structure of a cyanine dye and mitochondrial stain, JC-1, which is also an indicator
of mitochondrial polarization, as its aggregates have distinguishable fluorescence emission
wavelengths.

Quinones are a group of molecules that occur in several FDA-approved drugs and
treatments, namely doxorubicin and Mitomycin C. Doxorubicin is a current chemotherapeutic
agent, but has many adverse side effects, namely cardiotoxicity.78 Being that quinones and
anthraquinones are the backbone of these current cancer treatments, an imidazolium salt with an
anthraquinone substituent, AQ7 (Figure 2.7), was evaluated against bladder cancer cell lines.
Bladder cancer cell lines against which these imidazolium salts were evaluated include RT4,
RT112, UMUC3, UMUC13, SW780, TCCSUP, J82, and 5637 cells, which are epithelial
carcinoma cells from urinary bladder cancers.

Figure 2.7: Structure of AQ7, an anthraquinone-containing imidazolium salt. This compound was
synthesized by Michael Stromyer.77
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Results and Discussion
Evaluation of 10
Compound 10, which contains a triphenylphosphonium cationic substituent, was evaluated
against a series of bladder cancer cell lines to determine its efficacy after short exposure times.
Using a CellTiter Glo® assay, the GI50 values (growth inhibitory concentration for 50% of cells)
were determined for 10 against six different bladder cancer cell lines after a 1 h exposure to 10
(Figure 2.8). CellTiter Glo utilizes an enzyme that generates light in the presence of adenosine
triphosphate (ATP) When ATP is present, (that is, when the cell is alive) luciferase metabolizes
its substrate, luciferin, to generate light via chemiluminescence. Therefore, by comparing the
chemiluminescence observed for different treatment concentrations, the relative amounts of
cellular ATP can be determined, which directly correlates to the percent of cells that survive in
comparison to vehicle treatments.

Figure 2.8: Dose-response curve for 10 against six different bladder cancer cell lines with
exposure time of 1 h. GI50 values were calculated and displayed for each cell line. The horizontal
dotted line indicates 50% cell survival. Cells were treated in a 10% DMSO vehicle and relative
survival was compared to cells treated solely with 10% DMSO vehicle.
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Compound 10 shows toxicity against bladder cancer cell lines in the range of 80-240 μM
for a 1 h exposure. Longer exposure times would result in lower reported GI50 values but would
be impractical for intravesical treatment since retention time is limited before excretion. Since 10
is designed to be an intravesical agent, it is not expected that a patient will retain this
chemotherapeutic for times exceeding 1 h. Thus, shorter exposure times may prove to be beneficial
for the use of 10 intravesically. Growth inhibitory activity of 10 was measured for shorter exposure
times as well (Figure 2.9). RT4 and RT112 cells were treated with doses of 250 μM, 500 μM, or
1000 μM for 5, 15, and 30 min. Relative survival was compared vehicle (10% DMSO) treatment.
In RT4 cells, less than 50% of cells survived for all three concentrations of 10 in as little as 5 min
exposures. Comparatively, RT112 cells do not appear to be as sensitive to 10 as RT4 cells in
shorter exposure times; however, at the 1000 μM dose, there is substantial cell death in 15 min
exposures. DMSO is used as a vehicle for these treatments and for in vivo analysis; additionally,
it is used as an intravesical therapy for patients with chronic bladder pain syndrome.
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Figure 2.9: Relative survival of (A) RT4 cells and (B) RT112 cells after treatment of different
concentrations of 10 at various exposure times.
With twice the cationic charge as typical imidazolium salts, 10 is quite attracted to the
negative mitochondrial membrane potential. Given the toxicity of 10 and the mitochondrialtargeting triphenylphosphonium moiety, it was hypothesized that 10 was mitotoxic. To test this
hypothesis, mitochondria were isolated from RT112 cells using a Mitochondrial Isolation Kit
(ThermoFisher Scientific, #89874). A cell suspension was fractionated and processed to purify a
mitochondrial pellet, and the supernatant was replenished with fresh mitochondrial preservative
buffer as described in the literature.79 The pellet was treated for 1 h with 200 μM 10 (GI50 dose for
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RT112 cells for 1 h exposure). The mitochondrial pellet was allowed to recover for 1 and 4 h in
drug-free buffer, and the pellet was lysed, resolved with PAGE, and subjected to immunoblot.
Both the mitochondrial pellet and supernatant were probed for cytochrome c by Western blot
(Figure 2.10).

Figure 2.10: Western blot of isolated mitochondria from RT112 cells treated with vehicle, CCCP
(positive control) or 200 μM 10 for 1 h exposure and probed against cytochrome c. Times indicate
the recovery time allowed after the conclusion of incubation with drug solutions.
For isolated mitochondria treated with 10, after a 4 h recovery, there was substantial
cytochrome c released from the mitochondria into the supernatant. This is significant since
cytochrome c release from the mitochondria into the cytosol is the first step of the caspase cascade
for mitochondrial-induced apoptosis; therefore, the primary mechanism of cytotoxicity is believed
to be through this mitochondrial pathway. By isolating the mitochondria prior to treatment with
10, the drug’s target is unequivocally mitochondrial. For instance, cisplatin is known to induce
apoptosis by adducting and cross-linking DNA, resulting in p53 expression.80,81 p53 can induce
apoptosis by transactivating several proteins, such as Bax and PUMA, that induce mitochondrial
depolarization and cytochrome c release into the cytosol. 82,83 Thus, the release of cytochrome c
from the mitochondria strongly suggests that the mechanism of action is mitotoxicity, but does not
rule out other mechanisms of toxicity.
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Using the mitochondrial dye JC-1, confocal microscopy images were developed to show
the changing polarization of treated cells mitochondria (Figure 2.11). Red-orange color is
indicative of polarized, healthy mitochondria, whereas green staining signifies depolarized
mitochondria. Times indicated reflect recovery time allowed after the end of incubation with 10.
As shown, cell mitochondria begin to depolarize after 1 and 2 h, but after a 4 h recovery, almost
all of the cell mitochondria depolarized. Mitochondrial depolarization is a key step in the apoptotic
pathway and is consistent with the mitotoxic activity for 10.

Figure 2.11: Confocal microscopy images of RT112 cells treated with 10 and incubated with JC1. Red-orange color is indicative of polarized mitochondria, and green staining is depolarized
mitochondria. 10% DMSO is the vehicle treatment, CCCP is the positive control, and times
indicative recovery after conclusion of treatment with 10.
Evaluation of TCK1
TCK1, a cyanine dye, is a fluorescent imidazolium salt with good activity against a
multitude of cancer cell lines.77 Like 10, the suspected mechanism of toxicity is through a
mitochondrial pathway. To evaluate the biological activity against bladder cancer cell lines,
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CellTiter Glo assays were once again used, yielding IC50 values for 1 h exposures of TCK1 (Figure
2.12).

Figure 2.12: Dose-response curves for TCK1 against eight bladder cancer cell lines with 10%
DMSO vehicle. Results for 1 h exposure and compared to 10% DMSO vehicle.
Of the compounds examined, TCK1 exhibits the most potency, with GI50 values ranging
from 950 nM to 8.3 μM for the eight bladder cancer cell lines examined. Both UMUC3 and
UMUC13 show increased sensitivity to TCK1. These GI50 values were obtained after a clinically
practical 1 h exposure to TCK1, and the toxicity of TCK1 against RT112 cells and RT4 cells in
shorter exposure times was also evaluated (Figure 2.13).
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Figure 2.13: Relative survival of (A) RT4 cells and (B) RT112 cells treated with varying
concentrations of TCK1 for different exposure times. Cells treated in 10% DMSO vehicle and
relative survival compared to vehicle treatment.
RT4 cells and RT112 cells were treated with either a 5 μM, 10 μM, or 40 μM dose for 5,
15 or 30 min, then given a 24 h recovery before analysis. For RT4 treated cells, there is no
significant difference in the relative survival of cells treated with any of the three doses at 5 min
exposure. For RT112 cells, there is almost no cell survival for the 40 μM dose for 15 min exposure
times. This is significant since, if there is no systemic disadvantage to using higher doses, 15 min
exposures to TCK1 would result in substantial cancer cell death.
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To observe if TCK1 did in fact target the mitochondria, cells were treated with TCK1,
which fluoresces, and incubated with MitoView 405, a fluorescent mitochondrial stain. The inpixel overlap of TCK1 fluorescence with MitoView 405 fluorescence was then examined with
confocal microscopy (Figure 2.14).

Figure 2.14: Overlap of MitoView 405 and TCK1 in vitro. Green is mitochondrial staining, red is
TCK1 staining, and yellow shows the overlap of both. Color filters were altered for clarity.
The overlap of TCK1 with mitochondrial dyes is significant, as TCK1 accumulates in the
mitochondria as defined by pixels that also have a MitoView 405 signal. TCK1 has a wavelength
of maximum emission of 522 nm and MitoView 405 has a wavelength of maximum emission at
450 nm, but these colors were changed for clarity in Figure 2.14.
Known to accumulate in the mitochondria, TCK1 was determined to induce apoptosis
through a mitochondrial mechanism in a procedure similar to that of 10. Isolated mitochondria
from RT112 cells were treated with 5 μM TCK1 for 1 h. The drug treatment was then removed,
and mitochondria were resuspended in buffer. After 1 and 4 h recovery, the supernatant and
mitochondrial pellets were extracted and probed for cytochrome c (Figure 2.15).
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Figure 2.15: Mitochondria isolated from RT112 cells were treated with 5 μM TCK1 for 1 h, drug
treatment removed, and pellet allowed to recover for 1 or 4 h. Resulting suspension was
centrifuged, and mitochondrial and supernatant fractions were probed against cytochrome c.
Evidenced by the presence of cytochrome c in the supernatant of the mitochondrial
suspension, it was concluded that TCK1 proceeds through a mechanism of mitochondrial
apoptosis. Since isolated mitochondria expel cytochrome c after treatment with TCK1, it was
concluded that TCK1 functioned to disrupt the mitochondria, inducing apoptosis through a
mitochondrial pathway.
Evaluation of 3
Compound 3 was evaluated to determine its efficacy against bladder cancer cell lines. This
was done in the same manner as TCK1 and 10, with a 1 h exposure to the drug followed by 24 h
recovery and analysis using a CellTiter Glo assay. The dose response curves of 3 against eight
different bladder cancer cell lines highlight the cytotoxicity of 3 (Figure 2.16).
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Figure 2.16: Dose response curves for 3 against eight different bladder cancer cell lines with 25%
DMSO vehicle. Results for 1 h exposure, 24 h recovery, and relative survival compared to vehicle
treatment. Dotted horizontal line reflects 50% cell survival.
Compound 3 had GI50 values ranging from 19-42 μM for a 1 h exposure, thereby making
it more potent than 10 but less active than TCK1. This activity is also heightened when examining
UMUC3 and UMUC13 cell lines. The biological activity of 3 was also evaluated at shorter
exposure times in attempt to elucidate information about the rate of action and effective treatment
protocols in vivo. Relative survival was measured for RT112 cells and RT4 cells against doses of
50 and 100 μM 3 (Figure 2.17).
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Figure 2.17: Relative survival of (A) RT4 cells and (B) RT112 cells treated with varying
concentrations of 3 for different exposure times. Cells treated in 25% DMSO vehicle and relative
survival compared to vehicle treatment.
For both cell lines, a 100 μM dose of 3 resulted in significantly less cell proliferation in
comparison to the 50 μM dose for 15 and 30 min. For RT4 cells, a 100 μM dose results in less than
10% of cell survival, a marked improvement over the 50 μM dose. This enhanced cytotoxicity at
shorter exposure times may prove beneficial for administration of 3.
It is plausible that 3 follows the same mechanism of action as 10 and TCK1, as they are
mitochondrially-driven. The delocalized cation is believed to be attracted to the negative
mitochondrial membrane potential and should interact with the mitochondria, resulting in
apoptosis.
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Evaluation of AQ7
AQ7, an anthraquinone-containing imidazolium salt, was evaluated to determine its
biological activity and viability as a potential intravesical chemotherapeutic for NMIBC. Dose
response curves were generated for AQ7 for 1 h exposure, followed by a 24 h recovery (Figure
2.18).

Figure 2.18: Dose response curves of four different bladder cancer cell lines with 1 h exposure to
AQ7. Relative survival compared to vehicle measurements.
With GI50 values ranging from 32-50 μM, the observed cytotoxicity of AQ7 is around the
same as 3. Long-term effects of AQ7 were evaluated in vitro using colony forming assays. Cells
were plated sparsely and treated with AQ7 after fixing to the dish. After 1 h treatment, the drug
solution was removed, and fresh media was added. Cells were allowed to grow for 7-14 days
before being stained with crystal violet and imaged (Figure 2.19).
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Figure 2.19: Colony forming assays of (A) RT112 cells, (B) TCCSUP cells, (C) J82 cells, and (D)
UMUC13 cells after treatment with different concentrations of AQ7 with a 1 h exposure.
For RT112 and UMUC13 cells, there is minimal colony formation after the 7-14 day
recovery period for 50 μM doses, indicating that AQ7 is effective against these cell lines at around
the GI50 dose. For all four cell lines, there is not much difference between the 25 μM dose and the
vehicle control, indicating that AQ7 has a marginal impact as this low concentration. All cell lines
exhibit no colony formation for the 100 μM dose after at least 7 days.
Conclusions
Imidazolium salts have been shown to induce apoptosis in treated cells through a
mechanism of mitochondrial apoptosis and accumulate in the mitochondria. These drugs have

42

cytotoxicity in the micromolar range after just 1 h exposure, with some exhibiting substantial
cytotoxicity in as little as 5 min exposure. The most active compound examined was TCK1,
followed by 3 and AQ7, and then 10.
Although 10 is the least potent of the imidazolium salts studied, the TPP moiety enables it
to target the mitochondria, also allowing its selectivity against normal cells and tumor cells. 4
TCK1 also appears to exhibit similar myotoxicity by similar assays. Cytochrome c expulsion from
the mitochondria was detected at the same time point as mitochondrial depolarization, strongly
suggesting that the primary mechanism of toxicity is mitochondrially-driven, but other
mechanisms are feasible. Similar results were obtained for TCK1 and conjectured to hold for 3
based on their structural similarities. These imidazolium salts have shown tremendous potential as
intravesical therapies for NMIBC.
Experimental Section
General Considerations
Imidazolium salts were synthesized and purified by Michael Stromyer prior to use in vitro.
Confocal microscopy was done by Uttam Satyal with assistance from Andrey Efimov from the
Microscopy Facility at Fox Chase Cancer Center. All reagents and antibodies were used as
received with no further purification done. Reagents were purchased from Fisher Scientific, BD
Biosciences, Sigma Aldrich, Promega, and Biotium, Invitrogen, and GE Life Sciences. Cells were
grown in media as described by ATCC and incubated at 37° C and 5% CO2.
CellTiter Glo ® Assay
CellTiter Glo ® was prepared as instructed by manufacturer Promega. Bladder cancer cell
lines were plated in black-walled 96 well plates at 10000 cells/well and incubated for 24 h. Cells
were treated with drug in their respective media (as described by ATCC) at varying concentrations
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or vehicle for designated time, followed by the replacement of treatment media with normal growth
media. After 24 h, cells were incubated at room temperature for 30 min, followed by addition of
20 μL of CellTiter-Glo® luminescent cell viability assay reagent and vigorous mixing. After a 2
min room temperature incubation, luminescence for each plate was measured using IVIS. Relative
survival for each treatment group was calculated using vehicle control. All treatments were performed in quadruplicate.
Cytochrome c Release Study
RT112 cells (20 million) were grown in 15-cm dishes, then collected by scraping. Using a
mitochondrial extraction kit for mammalian cells (Thermo Scientific), a mitochondrial pellet was
obtained by following the manufacturer’s instructions. Pellets were treated with either 10%
DMSO, 100 μM CCCP, 200 μM 10, or 5 μM TCK1 for 1 h. The suspension was pelleted via
centrifugation (14,000 x g for 15 min) and the supernatant removed. Mitochondrial preservative
buffer was added as described in literature. 79 After 1 or 4 h recovery, the suspension was pelleted
and the mitochondrial pellet and supernatant fractions were saved for western blot analysis.
Western Blot Protocol
Mitochondrial pellets were lysed using a cocktail of RIPA buffer with protease and
phosphatase inhibitors. Lysates were mixed with sample buffers containing 50 mM DTT and
incubated at 95° C for 10 min. Proteins were separated with SDS-PAGE and transferred to a
nitrocellulose membrane permeabilized with methanol. Membranes were blocked with 5% milk
(nonfat) and stained with cytochrome c (BD Biosciences, #556432) primary antibody and HRPconjugated secondary antibody (Invitrogen, #31430) by incubating for 1 h with each antibody. The
blot was detected using an Amersham ECL kit (GE Life Sciences) and imaged on a FluorChem E
Digital Darkroom.
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Live Cell Imaging
In a 35 mm glass bottom microwell dish (MatTek Corp), 200,000 RT112 cells were plated
and incubated overnight. Cells were treated with 10 or TCK1 and allowed to incubate for 45 min.
JC-1 (EMD Millipore) or MitoView 405 (Biotium) was added to media to achieve a final
concentration as described by the manufacturer. Cells were imaged on Inverted Leica SP8 6
channels confocal microscope.
Colony Forming Assays
Cells were seeded at 500 cells/well in 6-well plates and incubated for 24 h. Cells were then
treated with vehicle or described concentrations of AQ7 for 1 h in triplicate. Treatment was
removed, and normal media was added and cells were allowed to grow for 10 days. Cells were
stained with crystal violet (0.5% crystal violet in 20% methanol:water) and incubated at 4° C for
5 min. Cells were then washed several times with DI water and imaged.
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Basic Precautions
Safety is imperative in chemical laboratories and reflect the highest ideals chemical
research. Basic lab safety should be a priority for all researchers, and anybody who uses chemical
or potentially hazardous substances should be aware of the proper procedures and precautions.
Among the most fundamental safety considerations are wearing gloves (chloroprene or nitrile),
wearing protective eye gear and other personal protective equipment (PPE), avoidance of food
and/or drink in the laboratory, no loose clothing or other accessories, and using chemicals in a
hood or other well-ventilated lab space. These guidelines were followed for all lab experiments.
To further improve the safety of lab space, researchers should be aware of all eyewash
stations, sinks, safety showers, and other safety stations located throughout the lab and
satisfactorily understand how to use each. In the event of any chemical spill or the contact to the
skin, the afflicted area should be washed for at least 15 minutes. One should also be aware of the
limitations of the gloves being used; for instance, acetonitrile easily passes through nitrile gloves,
so spilling this solvent even on gloves is hazardous.
In the event of a chemical spill or water spill, the liquid was properly contained and
absorbed. Solid chemicals that were spilled were swept up and disposed of in the solid waste
container. Halogenated and non-halogenated solvents and reagents were always separated and
disposed of into the proper waste containers. In biological labs, any surface that had contact with
biohazardous materials or cell culture equipment was washed with 70% ethanol and allowed to
dry.
The disposal of glass pipettes, broken glassware, pipette tips, used petri dishes or T75
flasks, and any other equipment used should be done so properly. Glass waste without biohazard
exposure should be disposed of in the indicated glass waste containers, and glass used in cell
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culture or other biological purposes should be disposed of in the biohazardous waste or sharps
container. All equipment that was used for biological purposes or that came into contact with
potentially biohazardous materials were disposed of in the marked biohazardous waste containers.
Before disposal of cancer cell lines, the cells were first washed with 10% bleach solution and
subsequently disposed of. Also, pipette tips or syringes used in the measurement of hazardous
chemicals or antibiotics (thionyl bromide, thionyl chloride, ethylene oxide, puromycin, cisplatin)
were disposed of promptly in sharps or other appropriately marked waste containers.
Chemical-Specific Precautions
There were several chemicals used in these reactions that are hazardous and dangerous
upon exposure. To mitigate this risk, proper protective action was taken. Listed are potentially
harmful reagents used and safety precautions taken.
Methyl iodide (CH3I) is a liquid causing severe skin irritation and eye irritation. Longsleeve lab coats were worn whenever handling these substances, and as always, protective eye
gear. A suspected carcinogen with serious effects on the central nervous system, care was used
when handling the substance under the supervision of a graduate student.

Figure S1: Structure of 2-(bromomethyl)naphthalene.
2-(bromomethyl)naphthalene (Figure S1) was stored at 4° C and used with care. An eye
irritant, safety eye gear was always worn when handling and gloves were promptly disposed of
after putting the compound away. Direct contact to the skin was avoided by wearing long-sleeve
PPE.
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Figure S2: Structure of o-phenylenediamine.
Another harmful substance is o-phenylenediamine (Figure S2), which was stored at room
temperature on a high shelf. Known as a suspected carcinogen, risk was diminished by using with
chloroprene gloves and long-sleeve PPE to avoid skin contact. Gloves were disposed of properly
after contact with o-phenylenediamine.

Figure S3: Structure of γ-butyrolactone.
A viscous liquid, γ-butyrolactone (Figure S3) was stored at 4° C and kept in an explosionproof refrigerator. This compound was transferred via a pipette, and the used pipette tip was
disposed of into the appropriate waste container immediately after use.

Figure S4: Structure of thionyl bromide.
Thionyl bromide (Figure S4) was particularly hazardous and handled with extreme care
under the supervision of a graduate student. Thionyl bromide was stored at 4° C and kept chilled
prior to use, as when this liquid warms up in the presence of atmospheric water, toxic vapors SO2
and HBr are formed. This compound was always used in a ventilated fume hood and never opened
outside of the hood. Because the reaction with water is violent and extremely exothermic, the
reaction flask was always well-secured and cooled upon addition. Safety masks were used to
reduce the risk of inhalation of these toxic vapors.
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Caustic acids and bases were also used in syntheses described. All acids (namely, HCl)
were measured and used inside of fume hood, as HCl gases are given off when using concentrated
HCl. Caustic bases (KOH) were also used in the syntheses described and in the cleaning of
glassware. Bases were weighed and immediately added to solution. When using the base bath,
protective eye gear, chloroprene gloves, rubber gloves, and a lab coat were used when opening the
base bath and retrieving glassware to avoid any injury. If any strong acid or base was splashed
onto gloves used, the gloves were promptly disposed of and skin washed with water.
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Compound Name
1: 4,5-dichloro-1,3-dimethyl-1H-imidazolium
iodide

Compound Structure

2: 1,3-bis(naphthalen-2-ylmethyl)-4,5diphenyl-1H-imidazolium bromide

3: 4,5-dichloro-1,3-bis(naphthalen-2ylmethyl)-1H-imidazolium bromide
4: 1,3-bis(naphthalen-2-ylmethyl)-1Himidazolium bromide
5: 1,3-bis(naphthalen-2-ylmethyl)-1Hbenzimidazolium bromide
6: 2-(4-bromophenyl)-1H-benzimidazole
7: 3-(1H-benzimidazol-2-yl)propan-1-ol

8: 2-(4-bromophenyl)-1,3-bis(naphthalen-2ylmethyl)-1H-benzimidazolium bromide

9: 2-(3-hydroxypropyl)-1,3-bis(naphthalen-2ylmethyl)-1H-benzimidazolium bromide
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10: 1,3-bis(naphthalen-2-ylmethyl)-2-(3(triphenylphosphonio)propyl)-1Hbenzimidazolium bromide

11: 4,5-dichloro-1,3-bis(naphthalen-2ylmethyl)-1,3-dihydro-2H-imidazole-2-thione

12: 1,3-bis(naphthalen-2-ylmethyl)-1,3dihydro-2H-imidazole-2-thione

13: 1,3-bis(naphthalen-2-ylmethyl)-1,3dihydro-2H-benzimidazole-2-thione

TCK1: 4,5-dichloro-2-((1E,3Z)-3-(3methylbenzoxazol-2(3H)-ylidene)prop-1-en1-yl)-1,3-bis(naphthalen-2-ylmethyl)-1Himidazolium chloride

AQ7: 1-((9,10-dioxo-9,10-dihydroanthracen2-yl)methyl)-3-(naphthalen-2-ylmethyl)-1Hbenzimidazolium bromide
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APPENDIX C: NMR SPECTRA

66

1

H NMR spectrum of 1 (300 MHz, DMSO-d6): δ 9.37 (s, 1 H, NCHN), 3.81 (s, 6 H, CH3).

67

1

H NMR spectrum of 2 (400 MHz, DMSO-d6): δ 9.79 (s, 1 H, NCHN), 7.92-7.89 (m, 4 H, Ar),

7.82-7.80 (m, 2 H, Ar), 7.59 (s, 2 H, Ar), 7.54-7.52 (m, 4 H, Ar), 7.37-7.30 (m, 12 H, Ar), 5.60 (s,
4 H, CH2).

1

H NMR spectrum for 3 (400 MHz, DMSO-d6): δ 9.80 (s, 1 H, NCHN), 8.03-7.94 (m, 8 H, Ar),

7.61-7.57 (m, 6 H, Ar), 5.71 (s, 4 H, CH2).

68

13

C NMR spectrum for 3 (400 MHz, DMSO-d6): δ 137.4, 133.2, 133.1, 130.5, 129.2, 128.3, 128.1,

127.3, 127.2, 126.0, 119.8, 52.3.

1

H NMR spectrum for 4 (400 MHz, DMSO-d6): δ 9.54 (s, 1 H, NCHN), 8.00-7.98 (d, 2 H, Ar),

7.97 (s, 2 H, Ar), 7.96-7.93 (m, 2 H, Ar), 7.92-7.90 (m, 4 H, Ar), 7.58-7.56 (m, 4 H, Ar), 7.54-7.53
(d, 2 H, Ar), 5.63 (s, 4 H, CH2).

69

1

H NMR spectrum for 5 (400 MHz, DMSO-d6): δ 10.20 (s, 1 H, NCHN), 8.11 (s, 2 H, Ar), 8.00-

7.98 (q, 2 H, Ar), 7.95-7.93 (d, 2 H, Ar), 7.91-7.87 (q, 2 H, Ar), 7.62 (d, 2 H, Ar), 7.60-7.59 (d, 2
H, Ar), 7.58-7.55 (q, 2 H, Ar), 7.53-7.50 (m, 4 H, Ar), 5.96 (s, 4 H, CH2).

1

H NMR spectrum for 6 (400 MHz, DMSO-d6): δ 12.92 (s, 1 H, NH), 8.08-8.05 (d, 2 H, Ar), 7.72-

7.70 (d, 2 H, Ar), 7.62-7.49 (m, 2 H, Ar), 7.17-7.16 (d, 2 H, Ar).

70

1

H NMR spectrum for 7 (400 MHz, DMSO-d6): δ 7.46-7.44 (m, 2 H, Ar), 7.11-7.09 (m, 2 H, Ar),

3.51-3.48 (t, 2 H, CH2OH), 2.87-2.83 (t, 2 H, CH2), 1.96-1.89 (p, 2 H, CH2).

1

H NMR spectrum for 8 (400 MHz, DMSO-d6): δ 8.09-8.05 (m, 2 H, Ar), 7.92-7.89 (m, 8 H, Ar),

7.84-7.81 (m, 2 H, Ar), 7.76 (s, 2 H, Ar), 7.70-7.67 (m, 2 H, Ar), 7.55-7.50 (m, 4 H, Ar), 7.38-7.35
(m, 2 H, Ar), 5.82 (s, 4 H, CH2).

71

1

H NMR spectrum for 9 (300 MHz, DMSO-d6): δ 8.00 (s, 2 H, Ar), 7.98-7.86 (m, 8 H, Ar), 7.57-

7.51 (m, 6 H, Ar), 7.48-7.47 (d, 2 H, Ar), 6.09 (s, 4 H, NCH2), 4.82 (s, 1 H, OH), 3.57-3.53 (t, 2
H, CH2), 3.50-3.46 (t, 2 H, CH2), 1.79-1.71 (p, 2 H, CH2).

1

H NMR spectrum for 10 (400 MHz, DMSO‑d6): δ 7.94-7.92 (m, 2 H, Ar), 7.90-7.86 (m, 6 H, Ar),

7.82-7.80 (m, 2 H, Ar), 7.75-7.72 (m, 3 H, Ar), 7.59-7.54 (m, 18 H, Ar), 7.47 (d, 2 H, Ar), 6.15 (s,
4 H, NCH2), 4.05-3.94 (m, 4 H, CH2), 1.90-1.86 (p, 2 H, CH2).

72

13

C NMR spectrum for 10 (400 MHz, DMSO‑d6): δ 153.2, 134.5, 133.0, 132.8, 132.4, 132.1,

131.5, 131.2, 129.8, 129.7, 128.3, 127.4, 126.3, 125.1, 124.4, 117.8, 117.0, 113.4, 48.6, 24.1, 20.3,
20.1.

31

P NMR spectrum for 10 (300 MHz, DMSO‑d6): δ 23.3.
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1

H NMR spectrum for 11 (400 MHz, DMSO-d6): δ 7.90-7.83 (m, 6 H, Ar), 7.76 (s, 2 H, Ar), 7.51-

7.47 (m, 6 H, Ar), 5.56 (s, 2 H, CH2).

1

H NMR spectrum for 12 (400 MHz, DMSO-d6): δ 7.87-7.80 (m, 6 H, Ar), 7.75 (s, 2 H, Ar), 7.48-

7.45 (m, 6 H, Ar), 7.21 (s, 2 H, NCH), 5.39 (s, 4 H, CH2).
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13

C NMR spectrum for 12 (400 MHz, DMSO-d6): δ 162.6, 134.6, 132.8, 132.4, 128.2, 127.7,

127.6, 126.4, 126.1, 125.8, 118.0, 50.2.

1

H NMR spectrum for 13 (400 MHz, DMSO-d6): δ 7.90-7.83 (m, 8 H, Ar), 7.56-7.54 (dd, 2 H,

Ar), 7.52-7.46 (m, 4 H, Ar), 7.41-7.38 (m, 2 H, Ar), 7.16-7.12 (m, 2 H, Ar), 5.83 (s, 4 H, CH2).
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